Nuvalent Inc
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitor… Read more
Nuvalent Inc (NUVL) - Net Assets
Latest net assets as of September 2025: $845.40 Million USD
Based on the latest financial reports, Nuvalent Inc (NUVL) has net assets worth $845.40 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($979.91 Million) and total liabilities ($134.51 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $845.40 Million |
| % of Total Assets | 86.27% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 4.94 |
Nuvalent Inc - Net Assets Trend (2019–2024)
This chart illustrates how Nuvalent Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nuvalent Inc (2019–2024)
The table below shows the annual net assets of Nuvalent Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.07 Billion | +52.71% |
| 2023-12-31 | $700.56 Million | +51.32% |
| 2022-12-31 | $462.98 Million | +62.43% |
| 2021-12-31 | $285.04 Million | +1009.99% |
| 2020-12-31 | $-31.32 Million | -81.52% |
| 2019-12-31 | $-17.26 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nuvalent Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 52972300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.00K | 0.00% |
| Other Comprehensive Income | $-59.00K | -0.01% |
| Other Components | $1.62 Billion | 151.14% |
| Total Equity | $1.07 Billion | 100.00% |
Nuvalent Inc Competitors by Market Cap
The table below lists competitors of Nuvalent Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Outfront Media Inc
NYSE:OUT
|
$4.43 Billion |
|
Janus Henderson Group PLC
NYSE:JHG
|
$4.43 Billion |
|
Punjab National Bank
NSE:PNB
|
$4.44 Billion |
|
Tokyu Fudosan
F:T8F
|
$4.44 Billion |
|
Ackermans & Van Haaren NV
PINK:AVHNF
|
$4.43 Billion |
|
Kingnet Network Co Ltd
SHE:002517
|
$4.42 Billion |
|
Fastighets AB Balder (publ)
PINK:BALDF
|
$4.42 Billion |
|
SHENWAN HONGYUAN GR.H YC1
F:2X2A
|
$4.41 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nuvalent Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 700,561,000 to 1,069,792,000, a change of 369,231,000 (52.7%).
- Net loss of 260,756,000 reduced equity.
- New share issuances of 569,987,000 increased equity.
- Other comprehensive income decreased equity by 90,000.
- Other factors increased equity by 60,090,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-260.76 Million | -24.37% |
| Share Issuances | $569.99 Million | +53.28% |
| Other Comprehensive Income | $-90.00K | -0.01% |
| Other Changes | $60.09 Million | +5.62% |
| Total Change | $- | 52.71% |
Book Value vs Market Value Analysis
This analysis compares Nuvalent Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.14x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.36 | $98.97 | x |
| 2020-12-31 | $-1.37 | $98.97 | x |
| 2021-12-31 | $13.08 | $98.97 | x |
| 2022-12-31 | $9.32 | $98.97 | x |
| 2023-12-31 | $12.03 | $98.97 | x |
| 2024-12-31 | $16.11 | $98.97 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nuvalent Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-24.37%) is below the historical average (-12.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.08 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.42 Million |
| 2021 | -16.26% | 0.00% | 0.00x | 1.03x | $-74.84 Million |
| 2022 | -15.84% | 0.00% | 0.00x | 1.04x | $-119.64 Million |
| 2023 | -18.02% | 0.00% | 0.00x | 1.05x | $-196.28 Million |
| 2024 | -24.37% | 0.00% | 0.00x | 1.07x | $-367.74 Million |
Industry Comparison
This section compares Nuvalent Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nuvalent Inc (NUVL) | $845.40 Million | 0.00% | 0.16x | $4.43 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |